Dermata Therapeutics Inc.

AI Score

0

Unlock

0.02
-0.00 (-18.37%)
At close: Mar 03, 2025, 1:18 PM
0.02
0.00%
After-hours: Mar 03, 2025, 01:18 PM EST
No 1D chart data available
Bid 0.02
Market Cap 49.8K
Revenue (ttm) n/a
Net Income (ttm) -14.79M
EPS (ttm) -2.156
PE Ratio (ttm) -0.01
Forward PE n/a
Analyst n/a
Ask 0.02
Volume 300
Avg. Volume (20D) 12,228.261
Open 0.02
Previous Close 0.02
Day's Range 0.02 - 0.02
52-Week Range 0.02 - 0.02
Beta 0.67

About DRMAW

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 13, 2021
Employees 8
Stock Exchange NASDAQ
Ticker Symbol DRMAW
Full Company Profile
No News article available yet